ArticleJournal of gastrointestinal oncology2026
Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zolbetuximab has improved survival in claudin 18.2 (CLDN18.2)-positive gastroesophageal adenocarcinoma (GEA). Hypoalbuminemia was reported in phase III trials. However, the timing, magnitude, and clinical phenotype of serum protein decline remain incompletely characterized. This study aimed to characterize changes in serum albumin and total protein during zolbetuximab therapy and their associated clinical findings. Methods: We performed a retrospective cohort study of patients with CLDN18.2-positive GEA treated with zolbetuximab at Mayo Clinic sites. The primary endpoint was percent change in serum albumin from baseline to the first post-treatment measurement following therapy initiation. Secondary endpoints included percent change in total protein, development of new edema or ascites not attributable to disease progression, and changes in albumin and total protein after treatment discontinuation. Results: Twenty-four patients were included. Serum albumin declined in all patients, and total protein declined in 23/24 (95.8%) immediately following treatment initiation. After the first cycle, median albumin decreased by 0.9 g/dL (22.5%), and total protein decreased by 1.5 g/dL (23.7%) from baseline. Ten patients (41.7%) developed new edema and 6 (25%) developed ascites, with 8 (33.3%) requiring diuretics and/or paracentesis, without radiographic disease progression. Renal and hepatic laboratory parameters remained stable, and urinalysis did not demonstrate nephrotic-range (grade 3+) proteinuria. Conclusions: Zolbetuximab therapy is associated with an early decline in serum albumin and total protein in real-world practice, frequently accompanied by edema or ascites and not explained by renal, hepatic, or progressive disease factors. These findings may reflect a treatment-related gastrointestinal protein-losing process and support close laboratory monitoring and supportive management during therapy. Further studies are warranted to clarify mechanism and clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.